ALEC — Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 175
- Website: https://www.alector.com
Latest SEC filings for ALEC
- FWP — 2026-10-16
- 424B5 — 2026-10-16
- SCHEDULE 13G — 2026-09-18
- 10-Q — 2026-08-06
- 8-K — 2026-08-06
- 8-K — 2026-07-08
- 8-K — 2026-06-17
- SCHEDULE 13G/A — 2026-05-14
- 8-K — 2026-05-07
- 10-Q — 2026-05-07
Latest ALEC news
- — Alector rises after pricing $75M equity offering (seekingalpha_market)
- — Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript (seekingalpha.com)
- — Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies (marketbeat.com)
- — Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
- — Alector surges on licensing agreement with Genentech (seekingalpha_market)
- — ALEC Stock Draws Big Passive Stake As Trading Heats Up - StocksToTrade (StocksToTrade)
- — Why is Alector stock surging today? By Investing.com - Investing.com India (Investing.com India)
- — Alector Licenses AL050 GCase Program to Genentech - TipRanks (TipRanks)
- — A Parkinson’s drug deal could mean up to $1.17 billion for Alector if future goals are met. - Stock Titan (Stock Titan)
- — Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases (globenewswire.com)
Educational tool only — not investment advice.